Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

About this update from Protagonist Therapeutics, Inc.

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies. The accepted abstracts provide additional perspective on the rusfertide clinical program in phlebotomy-dependent PV, including efficacy and safety outcomes across low-risk and high-risk patient subgroups, the effect of rusfertide on cytoreductive therapy use, long-term thromboembolic and disease progression events, and patient-reported symptom and fatigue measures. EHA2026 Presentations: Benefit of Rusfertide Maintained in Patients with Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis from the Randomized Controlled Phase 3 VERIFY StudyPresenting Author: Valentin Garcia GutierrezSession Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CESTPoster Number: PF892 Effect of Rusfertide on Cytoreductive Therapy Use in Patients with Phlebotomy Dependent Polycythemia Vera: Post Hoc Analysis from the Randomized Controlled Phase 3 VERIFY StudyPresenting Author: Francesca PalandriSession Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CESTPoster Number: PF891 Thromboembolic and Progression Events in Phlebotomy-Dependent Patients with Polycythemia Vera: Long-Term Results from the Phase 2 REVIVE and THRIVE Open-Label Extension Rusfertide StudiesPresenting Author: Naveen PemmarajuSession Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CESTPoster Number: PF890 Impact of Rusfertide on Polycythemia Vera-Related Symptoms and Patient-Reported Outcome-Related Items in the Randomized, Double-Blind Phase 3 VERIFY StudyPresenting Author: Alessandro LucchesiSession Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CESTPoster Number: PF898 About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics....

View stock analysis, news, and events for Protagonist Therapeutics, Inc.